Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy
Phase 2
Terminated
- Conditions
- Locally Advanced Sarcoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Questionnaire Administration
- First Posted Date
- 2016-04-08
- Last Posted Date
- 2021-08-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT02732015
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
Phase 2
Terminated
- Conditions
- LeukemiaAnemiaMyelofibrosisSplenomegaly
- Interventions
- Behavioral: Questionnaire
- First Posted Date
- 2016-04-07
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT02730884
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of TAK228 in Relapsed Lymphoma
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT02727777
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Personalized NK Cell Therapy in CBT
Phase 2
Recruiting
- Conditions
- Acute Myeloid Leukemia With Myelodysplasia-Related ChangesAcute Lymphoblastic LeukemiaISS Stage II Plasma Cell MyelomaAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaB Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1Chemotherapy-Related LeukemiaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsISS Stage III Plasma Cell MyelomaChronic Myelomonocytic Leukemia
- Interventions
- Biological: Allogeneic Natural Killer Cell Line NK-92Other: Laboratory Biomarker AnalysisRadiation: Total-Body IrradiationProcedure: Umbilical Cord Blood Transplantation
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT02727803
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
Phase 1
Active, not recruiting
- Conditions
- Stage III Ovarian Cancer AJCC v6 and v7Stage III Primary Peritoneal Cancer AJCC v7Stage IIIA Fallopian Tube Cancer AJCC v7Stage IIIB Fallopian Tube Cancer AJCC v7Stage IV Ovarian Cancer AJCC v6 and v7Stage IIIC Fallopian Tube Cancer AJCC v7Stage IIIC Primary Peritoneal Cancer AJCC v7Stage IV Fallopian Tube Cancer AJCC v6 and v7Stage IV Primary Peritoneal Cancer AJCC v7Stage III Fallopian Tube Cancer AJCC v7
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological StudyOther: Quality-of-Life Assessment
- First Posted Date
- 2016-04-04
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT02726997
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
Recruiting
- Conditions
- Smoldering Plasma Cell MyelomaMonoclonal Gammopathy of Undetermined Significance
- Interventions
- Procedure: Biospecimen CollectionOther: Laboratory Biomarker Analysis
- First Posted Date
- 2016-04-04
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT02726750
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ambu AuraGain and Teleflex LMA Protector Fiberoptic Assessments in Elective Patients
Not Applicable
Completed
- Conditions
- Anesthesia
- Interventions
- Device: Teleflex LMA ProtectorDevice: Ambu AuraGainDevice: Ambu aScope
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 53
- Registration Number
- NCT02724956
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
Phase 2
Active, not recruiting
- Conditions
- Carcinoma of Unknown PrimaryMetastatic Adrenal Gland PheochromocytomaMetastatic Malignant Germ Cell TumorMetastatic Skin Squamous Cell CarcinomaStage III Adrenal Cortex Carcinoma AJCC v7Small Cell CarcinomaUnresectable Skin Squamous Cell CarcinomaAdvanced Malignant Solid NeoplasmMetastatic ParagangliomaUnresectable Paraganglioma
- Interventions
- First Posted Date
- 2016-03-29
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 157
- Registration Number
- NCT02721732
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
EBUS TBNA After PET/CT in Diagnosing Patients With Stage I-IIA Non-small Cell Lung Cancer Evaluated for Stereotactic Body Radiation Therapy
Active, not recruiting
- Conditions
- Lung Cancer
- Interventions
- Procedure: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)
- First Posted Date
- 2016-03-25
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 150
- Registration Number
- NCT02719847
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies
Phase 2
Withdrawn
- Conditions
- Hematologic Malignancy
- Interventions
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02718755
© Copyright 2025. All Rights Reserved by MedPath